by John A. Jenkins | Jan 8, 2026 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: Growing Scrutiny of Drug Safety and Enforcement As GLP-1 weight-loss drugs surge in popularity, major news organizations are pressing the Food and Drug Administration for internal records that reveal what regulators knew about reports of dangers...
by John A. Jenkins | Dec 10, 2025 | FDA, FOIA, News Media, Pharmaceuticals
FOIAengine: The Investigative Outlet Gets Active at the FDA Capitol Forum may be one of the more under-the-radar journalistic enterprises in Washington, but recently it was easily the most active when it came to filing FOIA requests with the Food and Drug...
by Randy E. Miller | Oct 16, 2025 | FDA, FOIA
FOIAengine: FDA Weight Loss Drug FOIA Requests Grow Leading makers of GLP-1 (Glucagon-Like Peptide-1) weight loss drugs like Ozempic and Zepbound are facing off against domestic compounding pharmacies that import foreign ingredients and make cheaper, non-approved...
by Randy E. Miller | Sep 24, 2025 | FDA, FOIA, Law Firms, News Media, Non-Profits, Politics
FOIAengine: Over 100 FOIA Requests to Federal Agencies As the Trump Administration moves rapidly to install artificial intelligence throughout the federal government, a growing number of journalists, non-profits, lawyers, and executives are filing Freedom of...
by John A. Jenkins | Jul 17, 2025 | FDA, FOIA, Hedge Funds, Stock Market
FOIAengine: How a Proxy Requester Masks Its Identity On April 14, 2021, online forums where retail investors and short sellers exchange research, rumors, and trading strategies were buzzing. On Reddit and Twitter, meme stock traders were watching for the next big...
by John A. Jenkins | Jul 9, 2025 | FDA, FOIA, Hedge Funds, Stock Market
FOIAengine: Decoding How a Hedge Fund Tracks FDA Requests ExodusPoint burst onto the hedge fund scene in 2018 with the largest launch in history — raising $8.5 billion out of the gate — powered by institutional backing, an elite Wall Street pedigree, and high-profile...
